MXPA02009984A - Metodo y composicion para el tratamiento del cancer mediante la administracion de agentes quimioterapeuticos que inducen la apoptosis. - Google Patents
Metodo y composicion para el tratamiento del cancer mediante la administracion de agentes quimioterapeuticos que inducen la apoptosis.Info
- Publication number
- MXPA02009984A MXPA02009984A MXPA02009984A MXPA02009984A MXPA02009984A MX PA02009984 A MXPA02009984 A MX PA02009984A MX PA02009984 A MXPA02009984 A MX PA02009984A MX PA02009984 A MXPA02009984 A MX PA02009984A MX PA02009984 A MXPA02009984 A MX PA02009984A
- Authority
- MX
- Mexico
- Prior art keywords
- chemotherapeutic
- tumor
- composition
- administration
- treating cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 230000006907 apoptotic process Effects 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229940127089 cytotoxic agent Drugs 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 230000000973 chemotherapeutic effect Effects 0.000 abstract 9
- 230000000259 anti-tumor effect Effects 0.000 abstract 6
- 239000004005 microsphere Substances 0.000 abstract 4
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Las limitaciones de la tecnologia actual de los reservorios de quimioterapia pueden deberse a la retencion del quimioterapeutico solamente en la periferia del tumor o en la zona de inyeccion a causa de la pobre penetracion y distribucion del quimioterapeutico como resultado de la elevada presion del fluido intersticial del neoplasma. Un efecto anti-tumoral mas potente puede lograrse dirigiendo el quimioterapeutico directamente al tumor, es decir, intratumoralmente, antes que por infusion sistematica. Se especula que la entrada de las microesferas al tumor solido puede incrementarse aun mas si la inyeccion inicial de droga administrada para inducir la apoptosis consiste en una forma mas soluble de Taxol, es decir, paclitaxel/HSA, un complejo de Taxol y albumina, aumentando asi la apoptosis a lo largo de otros gradientes de presion. Ahora reportamos la aplicacion de un quimioterapeutico anti-cancerigeno, tal como paclitaxel, usando una composicion para la administracion local, a un paciente que tiene un tumor, de un quimioterapeutico anti-tumoral, tal como un reservorio quimiotrapeutico. La presente invencion comprende una pluralidad de microesferas que incorporan el quimioterapeutico anti-tumoral; y, una solucion de suspension que rodea las microesferas. Se saca ventaja de las proteinas de plasma, tal como HSA, para que actuen como un reservorio de liberacion lenta del quimioterapeutico anti-cancerigeno, tal como paclitaxel. La presente invencion proporciona una composicion para administrar un quimioterapeutico anti-tumoral como un reservorio quimioterapeutico a un paciente que presenta un tumor, la composicion comprende: una pluralidad de esferas que incorporan el quimioterapeutico anti-tumoral; y, una solucion de suspension que rodea las microesferas. La realizacion preferida consiste en una pluralidad de microesferas elaboradas a partir de una matriz polimerica biodegradable. Alternativamene, los reservorios pueden consistir en una pluralidad de microesferas elaboradas a partir de polimeros que no son biodegradables. La presente invencion proporciona ademas un metodo para la administracion de un quimioterapeutico anti-tumoral a un paciente que presenta un tumor, que comprende los pasos de aplicar el quimioterapeutico anti-tumoral como un reservorio quimioterapeutico para el tumor; y, liberar el quimioterapeutico anti-tumoral del reservorio quimioterapeutico a un espacio intersticial del tumor en una cantidad terapeuticamente efectiva, donde el reservorio quimioterapeutico incluye una pluralidad de microesferas que incorporan el quimioterapeutico anti-tumoral y una solucion de suspension que rodea las microesferas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19592000P | 2000-04-10 | 2000-04-10 | |
| PCT/US2001/011688 WO2001076567A1 (en) | 2000-04-10 | 2001-04-10 | Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02009984A true MXPA02009984A (es) | 2004-09-10 |
Family
ID=22723363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02009984A MXPA02009984A (es) | 2000-04-10 | 2001-04-10 | Metodo y composicion para el tratamiento del cancer mediante la administracion de agentes quimioterapeuticos que inducen la apoptosis. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20020041888A1 (es) |
| EP (1) | EP1274404A1 (es) |
| JP (1) | JP2004507451A (es) |
| KR (1) | KR20030008368A (es) |
| CN (1) | CN1438882A (es) |
| AU (1) | AU2001253334A1 (es) |
| BR (1) | BR0110150A (es) |
| CA (1) | CA2406484A1 (es) |
| CZ (1) | CZ20023333A3 (es) |
| EA (1) | EA200201068A1 (es) |
| HU (1) | HUP0302296A2 (es) |
| IL (1) | IL152180A0 (es) |
| MX (1) | MXPA02009984A (es) |
| NO (1) | NO20024867L (es) |
| PL (1) | PL366035A1 (es) |
| SK (1) | SK14452002A3 (es) |
| WO (1) | WO2001076567A1 (es) |
| YU (1) | YU77002A (es) |
| ZA (1) | ZA200208167B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20020680A1 (it) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento |
| ITMI20020681A1 (it) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina |
| KR20050026699A (ko) * | 2002-04-26 | 2005-03-15 | 테바 파마슈티컬 인더스트리즈 리미티드 | 종양내 전달을 위한 마이크로입자 약학 조성물 |
| CN1319525C (zh) * | 2004-09-16 | 2007-06-06 | 北京圣医耀科技发展有限责任公司 | 紫杉醇-海藻酸钠微球血管栓塞剂及其制备 |
| US8940311B2 (en) * | 2004-10-21 | 2015-01-27 | Tae-Hong Lim | In situ controlled release drug delivery system |
| KR101976003B1 (ko) | 2005-02-18 | 2019-05-09 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 조합 및 투여 방식, 및 조합 요법 |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US9233094B2 (en) | 2005-05-04 | 2016-01-12 | Medigene Ag | Method of administering a cationic liposomal preparation |
| AU2007228984B2 (en) | 2006-03-22 | 2012-05-03 | Syncore Biotechnology Co., Ltd | Treatment of triple receptor negative breast cancer |
| CA3087813A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Methods of treating cancer |
| KR20190109593A (ko) | 2010-03-29 | 2019-09-25 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
| MY162903A (en) | 2010-06-04 | 2017-07-31 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
| WO2012094620A2 (en) * | 2011-01-09 | 2012-07-12 | Anp Technologies, Inc. | Hydrophobic molecule-induced branched polymer aggregates and their use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4345588A (en) * | 1979-04-23 | 1982-08-24 | Northwestern University | Method of delivering a therapeutic agent to a target capillary bed |
| US4492720A (en) * | 1983-11-15 | 1985-01-08 | Benjamin Mosier | Method of preparing microspheres for intravascular delivery |
| HUP9701554D0 (en) * | 1997-09-18 | 1997-11-28 | Human Oltoanyagtermeloe Gyogys | Pharmaceutical composition containing plazma proteins |
-
2001
- 2001-04-10 MX MXPA02009984A patent/MXPA02009984A/es unknown
- 2001-04-10 CZ CZ20023333A patent/CZ20023333A3/cs unknown
- 2001-04-10 WO PCT/US2001/011688 patent/WO2001076567A1/en not_active Ceased
- 2001-04-10 IL IL15218001A patent/IL152180A0/xx unknown
- 2001-04-10 HU HU0302296A patent/HUP0302296A2/hu unknown
- 2001-04-10 JP JP2001574085A patent/JP2004507451A/ja active Pending
- 2001-04-10 BR BR0110150-1A patent/BR0110150A/pt not_active IP Right Cessation
- 2001-04-10 PL PL01366035A patent/PL366035A1/xx unknown
- 2001-04-10 SK SK1445-2002A patent/SK14452002A3/sk unknown
- 2001-04-10 US US09/829,621 patent/US20020041888A1/en not_active Abandoned
- 2001-04-10 CA CA002406484A patent/CA2406484A1/en not_active Abandoned
- 2001-04-10 AU AU2001253334A patent/AU2001253334A1/en not_active Abandoned
- 2001-04-10 CN CN01810833A patent/CN1438882A/zh active Pending
- 2001-04-10 KR KR1020027013576A patent/KR20030008368A/ko not_active Withdrawn
- 2001-04-10 EP EP01926824A patent/EP1274404A1/en not_active Withdrawn
- 2001-04-10 EA EA200201068A patent/EA200201068A1/ru unknown
-
2002
- 2002-04-10 YU YU77002A patent/YU77002A/sh unknown
- 2002-10-09 NO NO20024867A patent/NO20024867L/no not_active Application Discontinuation
- 2002-10-10 ZA ZA200208167A patent/ZA200208167B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001253334A1 (en) | 2001-10-23 |
| HUP0302296A2 (hu) | 2003-10-28 |
| WO2001076567A1 (en) | 2001-10-18 |
| NO20024867D0 (no) | 2002-10-09 |
| CZ20023333A3 (cs) | 2003-06-18 |
| ZA200208167B (en) | 2004-02-10 |
| NO20024867L (no) | 2002-12-06 |
| CN1438882A (zh) | 2003-08-27 |
| EP1274404A1 (en) | 2003-01-15 |
| CA2406484A1 (en) | 2001-10-18 |
| PL366035A1 (en) | 2005-01-24 |
| US20020041888A1 (en) | 2002-04-11 |
| EA200201068A1 (ru) | 2003-12-25 |
| JP2004507451A (ja) | 2004-03-11 |
| IL152180A0 (en) | 2003-05-29 |
| YU77002A (sh) | 2005-09-19 |
| KR20030008368A (ko) | 2003-01-25 |
| BR0110150A (pt) | 2004-04-27 |
| SK14452002A3 (sk) | 2003-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007003795A (es) | Oligoribonucleotidos y metodos de uso de los mismos para tratamiento de la alopecia, insuficiencia renal aguda y otras enfermedades. | |
| MXPA02009984A (es) | Metodo y composicion para el tratamiento del cancer mediante la administracion de agentes quimioterapeuticos que inducen la apoptosis. | |
| SG166775A1 (en) | Combinations and modes of administration of therapeutic agents and combination therapy | |
| TW200500355A (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
| MXPA03010121A (es) | Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales. | |
| WO2000049937A3 (en) | Trpm-2 antisense therapy | |
| MXPA05012155A (es) | Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades. | |
| IL244727A0 (en) | Methods and preparations using immunomodulatory compounds for the treatment and management of cancer and other diseases | |
| MXPA03007837A (es) | Composiciones para suministrar bisfosfonatos. | |
| NZ524138A (en) | Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents | |
| YU13603A (sh) | Postupci tretiranja poremećaja povenzanih sa bcl-2 primenom bcl-2 antisens oligomera | |
| IL153014A0 (en) | Barbituric acid analogs as therapeutic agents | |
| GEP20094798B (en) | (s,s)-reboxetine for treating chronic pain | |
| WO2001039762A3 (en) | Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system | |
| PL365285A1 (en) | Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs | |
| AU2002225772A1 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| MXPA02004676A (es) | Un metodo para quimioprevencion de cancer de prostata. | |
| MXPA03007857A (es) | Compuestos y composiciones para entregar agentes activos. | |
| MXPA02002681A (es) | Uso de metabolitos de acido alfa-linolenico para el tratamiento o prevencion del cancer. | |
| MXPA05003551A (es) | Composiciones y metodos para el tratamiento de prostata y otros canceres. | |
| IL151628A0 (en) | Combination therapies with vascular damaging activity | |
| WO2006043083A8 (en) | Liposomes enclosing a radionuclide and a cytotoxic agent for combination therapy | |
| WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
| EP1545479A4 (en) | EZETIMIB COMPOSITIONS AND METHOD FOR THE TREATMENT OF CHOLESTERIN-ASSOCIATED GOOD AND EVIL TUMORS | |
| MXPA03011270A (es) | Uso de antagonistas rank para tratar cancer. |